Paving the path toward multi-omics approaches in the diagnostic challenges faced in thyroid pathology

References

• Rosario PW, de Castro Nicolau T. The value of ultrasonography for the indication of fine-needle aspiration in autonomous thyroid nodules. Diagn Cytopathol. 2021;49:363–366. doi: 10.1002/dc.24659
   PubMed Web of Science ®Google Scholar
• Mistry R, Hillyar C, Nibber A, et al. Ultrasound classification of thyroid nodules: a systematic review. Cureus. 2020;12:e7239. doi: 10.7759/cureus.7239
   PubMed Web of Science ®Google Scholar
• Garber JR, Papini E, Frasoldati A, et al. American Association of clinical Endocrinology and Associazione Medici endocrinologi thyroid nodule algorithmic tool. Endocr Pract. 2021;27(7):649–660. doi: 10.1016/j.eprac.2021.04.007
   PubMed Web of Science ®Google Scholar
• Seminati D, Capitoli G, Leni D, et al. Use of diagnostic criteria from ACR and EU-TIRADS systems to improve the performance of cytology in thyroid nodule triage. Cancers. 2021;13(21):5439. doi: http://dx.doi.org/10.3390/cancers13215439
   PubMed Web of Science ®Google Scholar
• Leni D, Seminati D, Fior D, et al. Diagnostic performances of the ACR-TIRADS System in thyroid nodules triage: a prospective single center study. Cancers. 2021;13(9):2230. doi: http://dx.doi.org/10.3390/cancers13092230
   PubMed Web of Science ®Google Scholar
• Maxwell C, Sipos JA. Clinical Diagnostic Evaluation of Thyroid Nodules. Endocrinol Metab Clin North Am. 2019;48(1):61–84. doi: 10.1016/j.ecl.2018.11.001
   PubMed Web of Science ®Google Scholar
• Wang Z, Vyas CM, Van Benschoten O, et al. Quantitative analysis of the benefits and risk of thyroid nodule evaluation in patients ≥70 years old. Thyroid. 2018;28(4):465–471. doi: 10.1089/thy.2017.0655
   PubMed Web of Science ®Google Scholar
• Baloch Z, LiVolsi VA. The Bethesda System for reporting thyroid cytology (TBSRTC): from look-backs to look-ahead. Diagn Cytopathol. 2020;48:862–866. doi: 10.1002/dc.24385
   PubMed Web of Science ®Google Scholar
• Nardi F, Basolo F, Crescenzi A, et al. Italian consensus for the classification and reporting of thyroid cytology. J Endocrinol Invest. 2014;37(6):593–599. doi: 10.1007/s40618-014-0062-0
   PubMed Web of Science ®Google Scholar
• Asad Ullah M, Iqbal J, Ahmed MS, et al. Factors responsible for non-diagnostic cytology on ultrasound-guided fine-needle aspiration of thyroid nodules. Cureus. 2021;13:e14955. doi: 10.7759/cureus.14955
   PubMed Web of Science ®Google Scholar
• Ali SZ, Cibas ES The Bethesda System for reporting thyroid Cytopathology: definitions, criteria, and explanatory notes. Springer; 2017.
   Google Scholar
• Poller DN, Cochand-Priollet B, Trimboli P. Thyroid FNA terminology: the case for a single unified international system for thyroid FNA reporting. Cytopathology. 2021;32:714–717.
   PubMed Web of Science ®Google Scholar
• Christofer Juhlin C, Mete O, Baloch ZW. The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr Relat Cancer. 2023;30. doi: 10.1530/ERC-22-0293
   PubMed Web of Science ®Google Scholar
• Canini V, Leni D, Pincelli AI, et al. Clinical-pathological issues in thyroid pathology: study on the routine application of NIFTP diagnostic criteria. Sci Rep. 2019;9(1):13179. doi: 10.1038/s41598-019-49851-1
   PubMedGoogle Scholar
• Nishino M, Nikiforova M. Update on molecular testing for cytologically indeterminate thyroid nodules. Arch Pathol Lab Med. 2018;142(4):446–457. doi: 10.5858/arpa.2017-0174-RA
   PubMed Web of Science ®Google Scholar
• Caputo A, L’Imperio V, Merolla F, et al. The slow-paced digital evolution of pathology: lights and shadows from a multifaceted board. Pathologica. 2023;115(3):127–136. doi: 10.32074/1591-951X-868
   PubMed Web of Science ®Google Scholar
• L’Imperio V, Casati G, Cazzaniga G, et al. Improvements in digital pathology equipment for renal biopsies: updating the standard model. J Nephrol. 2023. doi:10.1007/s40620-023-01568-1
   Web of Science ®Google Scholar
• Pisapia P, L’Imperio V, Galuppini F, et al. The evolving landscape of anatomic pathology. Crit Rev Oncol Hematol. 2022;178:103776. doi: 10.1016/j.critrevonc.2022.103776
   PubMed Web of Science ®Google Scholar
• Caputo A, Gibilisco F, Belmonte B, et al. Real-world digital pathology: considerations and ruminations of four young pathologists. J Clin Pathol. 2023;76(1):68–70. doi: 10.1136/jclinpath-2022-208218
   PubMed Web of Science ®Google Scholar
• L’Imperio V, Brambilla V, Cazzaniga G, et al. Digital pathology for the routine diagnosis of renal diseases: a standard model. J Nephrol. 2021;34(3):681–688. doi: 10.1007/s40620-020-00805-1
   PubMed Web of Science ®Google Scholar
• L’Imperio V, Wulczyn E, Plass M, et al. Pathologist validation of a machine learning-derived feature for colon cancer risk stratification. JAMA Netw Open. 2023;6:e2254891. doi: 10.1001/jamanetworkopen.2022.54891
   PubMed Web of Science ®Google Scholar
• Bindi G, Smith A, Oliveira G, et al. Spatial resolution of renal amyloid deposits through MALDI-MSI: a combined digital and molecular approach to monoclonal gammopathies. J Clin Pathol. 2023. doi: 10.1136/jcp-2023-208790
   PubMed Web of Science ®Google Scholar
• Piga I, Casano S, Smith A, et al. Update on: proteome analysis in thyroid pathology - part II: overview of technical and clinical enhancement of proteomic investigation of the thyroid lesions. Expert Rev Proteomics. 2018;15:937–948. doi: 10.1080/14789450.2018.1532793
   PubMed Web of Science ®Google Scholar
• Han R-L, Wang J, Zhang F-J, et al. Ultrasound risk assessment combined with molecular markers of galectin-3, c-MET, HBME-1 and CK19 for diagnosis of malignant and benign thyroid nodules. Pathol Oncol Res. 2019;25(3):1075–1081. doi: 10.1007/s12253-018-0485-6
   PubMed Web of Science ®Google Scholar
• Huang L, Wang X, Huang X, et al. Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma. Oncol Lett. 2018;15:4269–4277. doi: 10.3892/ol.2018.7873
   PubMed Web of Science ®Google Scholar
• Xiong Y, Li X, Liang L, et al. Application of biomarkers in the diagnosis of uncertain samples of core needle biopsy of thyroid nodules. Virchows Arch. 2021;479(5):961–974. doi: 10.1007/s00428-021-03161-y
   PubMed Web of Science ®Google Scholar
• Song S, Kim H, Ahn S-H. Role of immunohistochemistry in fine needle aspiration and core needle biopsy of thyroid nodules. Clin Exp Otorhinolaryngol. 2019;12(2):224–230. doi: 10.21053/ceo.2018.01011
   PubMed Web of Science ®Google Scholar
• Scarpino S, Di Napoli A, Melotti F, et al. Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J Pathol. 2007;212(4):411–419. doi: 10.1002/path.2183
   PubMed Web of Science ®Google Scholar
• El Demellawy D, Nasr AL, Babay S, et al. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid. Pathol Res Pract. 2009;205(5):303–309. doi: 10.1016/j.prp.2008.11.011
   PubMed Web of Science ®Google Scholar
• Park WY, Jeong SM, Lee JH, et al. Diagnostic value of decreased expression of CD56 protein in papillary carcinoma of the thyroid gland. Basic Appl Pathol. 2009;2(2):63–68. doi: 10.1111/j.1755-9294.2009.01045.x
   Google Scholar
• Solmaz OA. Diagnostic importance of CD56 with fine-needle aspiration cytology in suspected papillary thyroid carcinoma cases. Cytojournal. 2018;15:3. doi: 10.4103/cytojournal.cytojournal_42_17
   PubMed Web of Science ®Google Scholar
• Cha H, Pyo JY, Hong SW. The usefulness of immunocytochemistry of CD56 in determining malignancy from indeterminate thyroid fine-needle aspiration cytology. J Pathol Transl Med. 2018;52(6):404–410. doi: 10.4132/jptm.2018.09.20
   PubMed Web of Science ®Google Scholar
• Bizzarro T, Martini M, Marrocco C, et al. The role of CD56 in thyroid fine needle aspiration cytology: a Pilot study performed on liquid based cytology. PLoS One. 2015;10(7):e0132939. doi: 10.1371/journal.pone.0132939
   PubMed Web of Science ®Google Scholar
• Kwaspen FH, Smedts FM, Broos A, et al. Reproducible and highly sensitive detection of the broad spectrum epithelial marker keratin 19 in routine cancer diagnosis. Histopathology. 1997;31(6):503–516. doi: 10.1046/j.1365-2559.1997.2960896.x
   PubMed Web of Science ®Google Scholar
• Sethi K, Sarkar S, Das S, et al. Biomarkers for the diagnosis of thyroid cancer. J Exp Ther Oncol. 2010;8:341–352.
   PubMedGoogle Scholar
• Park YJ, Kwak SH, Kim DC, et al. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci. 2007;22:621–628. doi: 10.3346/jkms.2007.22.4.621
   PubMed Web of Science ®Google Scholar
• Nechifor-Boilă A, Cătană R, Loghin A, et al. Diagnostic value of HBME-1, CD56, galectin-3 and cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential. Rom J Morphol Embryol. 2014;55:49–56.
   PubMed Web of Science ®Google Scholar
• Barroeta JE, Baloch ZW, Lal P, et al. Diagnostic value of differential expression of CK19, galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol. 2006;17:225–234. doi: 10.1385/EP:17:3:225
   PubMed Web of Science ®Google Scholar
• Zhu X, Sun T, Lu H, et al. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. J Clin Pathol. 2010;63(9):786–789. doi: 10.1136/jcp.2010.076901
   PubMed Web of Science ®Google Scholar
• Scognamiglio T, Hyjek E, Kao J, et al. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol. 2006;126(5):700–708. doi: 10.1309/044V86JN2W3CN5YB
   PubMed Web of Science ®Google Scholar
• Nasr MR, Mukhopadhyay S, Zhang S, et al. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining. Mod Pathol. 2006;19(12):1631–1637. doi: 10.1038/modpathol.3800705
   PubMed Web of Science ®Google Scholar
• Dunđerović D, Lipkovski JM, Boričic I, et al. Defining the value of CD56, CK19, galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature. Diagn Pathol. 2015;10(1):196. doi: 10.1186/s13000-015-0428-4
   PubMedGoogle Scholar
• Xu XC, el-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol. 1995;147:815–822.
   PubMed Web of Science ®Google Scholar
• Liu F-T, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5(1):29–41. doi: 10.1038/nrc1527
   PubMed Web of Science ®Google Scholar
• Liu YY, Morreau H, Kievit J, et al. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol. 2008;158:375–384. doi: 10.1530/EJE-07-0492
   PubMed Web of Science ®Google Scholar
• Raouf SM A-E, Ibrahim TR. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules. Pathol Res Pract. 2014;210:971–978. doi: 10.1016/j.prp.2014.06.010
   PubMed Web of Science ®Google Scholar
• Inohara H, Segawa T, Miyauchi A, et al. Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Biochem Biophys Res Commun. 2008;376(3):605–610. doi: 10.1016/j.bbrc.2008.09.041
   PubMed Web of Science ®Google Scholar
• Sapio MR, Guerra A, Posca D, et al. Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer. 2007;14(4):1089–1097. doi: 10.1677/ERC-07-0147
   PubMed Web of Science ®Google Scholar
• Nucera C, Mazzon E, Caillou B, et al. Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia. J Endocrinol Invest. 2005;28(4):106–112. doi: 10.1007/BF03345351
   PubMedGoogle Scholar
• Zhang L, Krausz T, DeMay RM. A Pilot study of galectin-3, HBME-1, and p27 triple immunostaining pattern for diagnosis of indeterminate thyroid nodules in cytology with correlation to histology. Appl Immunohistochem Mol Morphol. 2015;23(7):481–490. doi: 10.1097/PAI.0000000000000106
   PubMedGoogle Scholar
• Weber KB, Shroyer KR, Heinz DE, et al. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol. 2004;122(4):524–531. doi: 10.1309/UUQTE505PTN5QJ7M
   PubMed Web of Science ®Google Scholar
• Cazzaniga G, Seminati D, Smith A, et al. Lights on HBME-1: the elusive biomarker in thyroid cancer pathology. J Clin Pathol. 2022;75(9):588–592. doi: 10.1136/jclinpath-2022-208248
   PubMed Web of Science ®Google Scholar
• Volante M, Bozzalla-Cassione F, DePompa R, et al. Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch. 2004;445(2):183–188. doi: 10.1007/s00428-004-1074-5
   PubMed Web of Science ®Google Scholar
• Mase T, Funahashi H, Koshikawa T, et al. HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J. 2003;50(2):173–177. doi: 10.1507/endocrj.50.173
   PubMed Web of Science ®Google Scholar
• Ito Y, Yoshida H, Tomoda C, et al. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. Anticancer Res. 2005;25:179–182.
   PubMed Web of Science ®Google Scholar
• Mai KT, Bokhary R, Yazdi HM, et al. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with hürthle cell and/or apocrine-like changes. Histopathology. 2002;40(2):133–142. doi: 10.1046/j.1365-2559.2002.01315.x
   PubMed Web of Science ®Google Scholar
• Sadiq Q, Sekhri R, Dibaba DT, et al. HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions. World J Surg Oncol. 2021;19(1):143. doi: 10.1186/s12957-021-02258-7
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954. doi: 10.1038/nature00766
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742–762. doi: 10.1210/er.2007-0007
   PubMed Web of Science ®Google Scholar
• Fagin JA, SA W Jr. Biologic and clinical perspectives on thyroid cancer. 2016 [cited 2023 Jul 27]. Available from: https://www.nejm.org/doi/10.1056/NEJMra1501993.
   Google Scholar
• Choden S, Keelawat S, Jung CK, et al. VE1 immunohistochemistry improves the limit of genotyping for detecting BRAFV600E mutation in papillary thyroid cancer. Cancers. 2020;12(3):596. doi: 10.3390/cancers12030596
   PubMed Web of Science ®Google Scholar
• Kim M, Jeon S, Jung CK. Preoperative risk stratification of follicular-patterned thyroid lesions on core needle biopsy by histologic subtyping and RAS variant-specific immunohistochemistry. Endocr Pathol. 2023;34(2):247–256. doi: 10.1007/s12022-023-09763-3
   PubMed Web of Science ®Google Scholar
• Marchiò C, Scaltriti M, Ladanyi M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019;30(9):1417–1427. doi: 10.1093/annonc/mdz204
   PubMed Web of Science ®Google Scholar
• Macerola E, Proietti A, Poma AM, et al. Limited accuracy of pan-trk immunohistochemistry screening for rearrangements in follicular-derived thyroid carcinoma. IJMS. 2022;23:7470. doi: http://dx.doi.org/10.3390/ijms23137470
   Google Scholar
• Rosenbaum JN, Guo Z, Baus RM, et al. INSM1: a novel Immunohistochemical and molecular marker for neuroendocrine and neuroepithelial neoplasms. Am J Clin Pathol. 2015;144(4):579–591. doi: 10.1309/AJCPGZWXXBSNL4VD
   PubMed Web of Science ®Google Scholar
• Hou T, Gan Q, Joseph CT, et al. Insulinoma-associated protein 1 immunostaining for various types of neuroendocrine tumors on FNA smears. Cancer Cytopathol. 2020;128:725–732. doi: 10.1002/cncy.22310
   PubMed Web of Science ®Google Scholar
• Maleki Z, Abram M, Dell’aquila M, et al. Insulinoma-associated protein 1 (INSM-1) expression in medullary thyroid carcinoma FNA: a multi-institutional study. J Am Soc Cytopathol. 2020;9(3):185–190. doi: 10.1016/j.jasc.2020.01.005
   PubMedGoogle Scholar
• Belovarac B, Zhou F, Sharma J, et al. Indeterminate thyroid nodules and advances in molecular pathology. Semin Diagn Pathol. 2023;40(5):349–352. doi: http://dx.doi.org/10.1053/j.semdp.2023.05.001
   PubMed Web of Science ®Google Scholar
• Glass RE, Marotti JD, Kerr DA, et al. Using molecular testing to improve the management of thyroid nodules with indeterminate cytology: an institutional experience with review of molecular alterations. J Am Soc Cytopathol. 2022;11(2):79–86. doi: 10.1016/j.jasc.2021.08.004
   PubMedGoogle Scholar
• Livhits MJ, Zhu CY, Kuo EJ, et al. Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules: a randomized clinical trial. JAMA Oncol. 2021;7(1):70–77. doi: 10.1001/jamaoncol.2020.5935
   PubMed Web of Science ®Google Scholar
• Park H, Shin HC, Yang H, et al. Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations. Mod Pathol. 2022;35(2):186–192. doi: 10.1038/s41379-021-00907-6
   PubMed Web of Science ®Google Scholar
• Patel KN, Angell TE, Babiarz J, et al. Performance of a Genomic sequencing Classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules. JAMA Surg. 2018;153(9):817–824. doi: 10.1001/jamasurg.2018.1153
   PubMed Web of Science ®Google Scholar
• Lee E, Terhaar S, McDaniel L, et al. Diagnostic performance of the second-generation molecular tests in the assessment of indeterminate thyroid nodules: a systematic review and meta-analysis. Am J Otolaryngol. 2022;43:103394. doi: 10.1016/j.amjoto.2022.103394
   PubMed Web of Science ®Google Scholar
• Gortakowski M, Feghali K, Osakwe I. Single institution experience with Afirma and thyroseq testing in indeterminate thyroid nodules. Thyroid. 2021;31(9):1376–1382. doi: 10.1089/thy.2020.0801
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Lepe M, Tolino LA, et al. Thyroid cytology smear slides: an untapped resource for ThyroSeq testing. Cancer Cytopathol. 2021;129:33–42. doi: 10.1002/cncy.22331
   PubMed Web of Science ®Google Scholar
• Steward DL, Carty SE, Sippel RS, et al. Performance of a multigene genomic Classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study. JAMA Oncol. 2019;5(2):204–212. doi: 10.1001/jamaoncol.2018.4616
   PubMed Web of Science ®Google Scholar
• Ohori NP, Landau MS, Carty SE, et al. Benign call rate and molecular test result distribution of ThyroSeq v3. Cancer Cytopathol. 2019;127:161–168. doi: 10.1002/cncy.22088
   PubMed Web of Science ®Google Scholar
• Lupo MA, Walts AE, Sistrunk JW, et al. Multiplatform molecular test performance in indeterminate thyroid nodules. Diagn Cytopathol. 2020;48:1254–1264. doi: 10.1002/dc.24564
   PubMed Web of Science ®Google Scholar
• Gooding WE, Chiosea SI. Alternate diagnostic test interpretation in a retrospective convenience cohort and clinical application of MPTX. Diagn Cytopathol. 2021;49:347–348. doi: 10.1002/dc.24656
   PubMed Web of Science ®Google Scholar
• Smith A, L’Imperio V, Denti V, et al. High spatial resolution MALDI-MS imaging in the study of Membranous nephropathy. Proteomics Clin Appl. 2019;13(1):e1800016. doi: 10.1002/prca.201800016
   PubMed Web of Science ®Google Scholar
• Schober Y, Guenther S, Spengler B, et al. Single cell matrix-assisted laser desorption/ionization mass spectrometry imaging. Anal Chem. 2012;84(15):6293–6297. doi: 10.1021/ac301337h
   PubMed Web of Science ®Google Scholar
• McMillen JC, Gutierrez DB, Judd AM, et al. Enhancement of tryptic peptide signals from tissue sections using MALDI IMS postionization (MALDI-2). J Am Soc Mass Spectrom. 2021;32(10):2583–2591. doi: 10.1021/jasms.1c00213
   PubMed Web of Science ®Google Scholar
• Meier F, Brunner A-D, Frank M, et al. diaPASEF: parallel accumulation-serial fragmentation combined with data-independent acquisition. Nat Methods. 2020;17:1229–1236. doi: 10.1038/s41592-020-00998-0
   PubMed Web of Science ®Google Scholar
• Denti V, Capitoli G, Piga I, et al. Correction to spatial multiomics of lipids, N-Glycans, and tryptic peptides on a single FFPE tissue Section. J Proteome Res. 2023;22(6):2149. doi: 10.1021/acs.jproteome.3c00217
   PubMed Web of Science ®Google Scholar
• Yagnik G, Liu Z, Rothschild KJ, et al. Highly multiplexed Immunohistochemical MALDI-MS imaging of biomarkers in tissues. J Am Soc Mass Spectrom. 2021;32(4):977–988. doi: 10.1021/jasms.0c00473
   PubMed Web of Science ®Google Scholar
• Lim MJ, Yagnik G, Henkel C, et al. MALDI HiPLEX-IHC: multiomic and multimodal imaging of targeted intact proteins in tissues. Front Chem. 2023;11:1182404. doi: 10.3389/fchem.2023.1182404
   PubMed Web of Science ®Google Scholar
• Heijs B, Holst S, Briaire-de Bruijn IH, et al. Multimodal mass spectrometry imaging of N-Glycans and proteins from the same tissue Section. Anal Chem. 2016;88(15):7745–7753. doi: 10.1021/acs.analchem.6b01739
   PubMed Web of Science ®Google Scholar
• Ciregia F, Giusti L, Molinaro A, et al. Proteomic analysis of fine-needle aspiration in differential diagnosis of thyroid nodules. Transl Res. 2016;176:81–94. doi: 10.1016/j.trsl.2016.04.004
   PubMed Web of Science ®Google Scholar
• Wu C-C, Lin J-D, Chen J-T, et al. Integrated analysis of fine-needle-aspiration cystic fluid proteome, cancer cell secretome, and public transcriptome datasets for papillary thyroid cancer biomarker discovery. Oncotarget. 2018;9(15):12079–12100. doi: 10.18632/oncotarget.23951
   PubMedGoogle Scholar
• Lin P, Yao Z, Sun Y, et al. Deciphering novel biomarkers of lymph node metastasis of thyroid papillary microcarcinoma using proteomic analysis of ultrasound-guided fine-needle aspiration biopsy samples. J Proteomics. 2019;204:103414. doi: 10.1016/j.jprot.2019.103414
   PubMed Web of Science ®Google Scholar
• Kostrzewa M. Application of the MALDI Biotyper to clinical microbiology: progress and potential. Expert Rev Proteomics. 2018;15(3):193–202. doi: 10.1080/14789450.2018.1438193
   PubMed Web of Science ®Google Scholar
• Piga I, Capitoli G, Denti V, et al. The management of haemoglobin interference for the MALDI-MSI proteomics analysis of thyroid fine needle aspiration biopsies. Anal Bioanal Chem. 2019;411(20):5007–5012. doi: 10.1007/s00216-019-01908-w
   PubMed Web of Science ®Google Scholar
• Piga I, Capitoli G, Clerici F, et al. Ex vivo thyroid fine needle aspirations as an alternative for MALDI-MSI proteomic investigation: intra-patient comparison. Anal Bioanal Chem. 2021;413(5):1259–1266. doi: 10.1007/s00216-020-03088-4
   PubMed Web of Science ®Google Scholar
• Piga I, Capitoli G, Tettamanti S, et al. Feasibility study for the MALDI-MSI analysis of thyroid fine needle aspiration biopsies: evaluating the morphological and proteomic stability over time. Proteomics Clin Appl. 2019;13(1):e1700170. doi: 10.1002/prca.201700170
   PubMed Web of Science ®Google Scholar
• Piga I, Pagni F, Magni F, et al. Cytological cytospin preparation for the spatial proteomics analysis of thyroid nodules using MALDI-MSI. Methods Mol Biol. 2023;2688:95–105.
   PubMedGoogle Scholar
• Capitoli G, Piga I, Galimberti S, et al. MALDI-MSI as a complementary diagnostic tool in Cytopathology: a Pilot study for the characterization of thyroid nodules. Cancers. 2019;11:11. doi: 10.3390/cancers11091377
   Web of Science ®Google Scholar
• Capitoli G, Piga I, Clerici F, et al. Analysis of Hashimoto’s thyroiditis on fine needle aspiration samples by MALDI-Imaging. Biochim Biophys Acta Proteins Proteomics. 2020;1868(11):140481. doi: 10.1016/j.bbapap.2020.140481
   PubMed Web of Science ®Google Scholar
• Piga I, Capitoli G, Clerici F, et al. Molecular trait of follicular-patterned thyroid neoplasms defined by MALDI-imaging. Biochim Biophys Acta Proteins Proteomics. 2020;1868(11):140511. doi: 10.1016/j.bbapap.2020.140511
   PubMed Web of Science ®Google Scholar
• Capitoli G, Piga I, L’Imperio V, et al. Cytomolecular classification of thyroid nodules using fine-needle washes aspiration biopsies. IJMS. 2022;23(8):4156. doi: 10.3390/ijms23084156
   Google Scholar
• Ye G, Zhang X, Li M, et al. Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer. BMC Cancer. 2023;23(1):412. doi: 10.1186/s12885-023-10839-w
   PubMed Web of Science ®Google Scholar
• Wei W, Wu Y, Chen D-D, et al. Proteomics profiling for the global and acetylated proteins of papillary thyroid cancers. Proteome Sci. 2023;21(1):6. doi: 10.1186/s12953-023-00207-8
   PubMed Web of Science ®Google Scholar
• Zhan S, Li J, Wang T, et al. Quantitative proteomics analysis of sporadic medullary thyroid cancer reveals FN1 as a potential novel candidate prognostic biomarker. Oncology. 2018;23(12):1415–1425. doi: 10.1634/theoncologist.2017-0399
   Google Scholar
• Li J, Mi L, Ran B, et al. Identification of potential diagnostic and prognostic biomarkers for papillary thyroid microcarcinoma (PTMC) based on TMT-labeled LC-MS/MS and machine learning. J Endocrinol Invest. 2023;46:1131–1143. doi: 10.1007/s40618-022-01960-x
   PubMed Web of Science ®Google Scholar
• Zhan S, Wang T, Wang M, et al. In-depth proteomics analysis to identify biomarkers of papillary thyroid cancer patients older than 45 years with different degrees of lymph node metastases. Proteomics Clin Appl. 2019;13(5):e1900030. doi: 10.1002/prca.201900030
   PubMed Web of Science ®Google Scholar
• Jin S, Bao W, Yang Y-T, et al. Proteomic analysis of the papillary thyroid microcarcinoma. Ann Endocrinol. 2019;80(5–6):293–300. doi: 10.1016/j.ando.2019.01.003
   PubMed Web of Science ®Google Scholar
• Cao Z, Zhang Z, Tang X, et al. Comprehensive analysis of tissue proteomics in patients with papillary thyroid microcarcinoma uncovers the underlying mechanism of lymph node metastasis and its significant sex disparities. Front Oncol. 2022;12:887977. doi: 10.3389/fonc.2022.887977
   PubMed Web of Science ®Google Scholar
• Gawin M, Kurczyk A, Stobiecka E, et al. Molecular heterogeneity of papillary thyroid cancer: comparison of primary tumors and synchronous metastases in regional lymph nodes by mass spectrometry imaging. Endocr Pathol. 2019;30(4):250–261. doi: 10.1007/s12022-019-09593-2
   PubMed Web of Science ®Google Scholar
• Lu J, Zhang Y, Sun M, et al. Multi-omics analysis of fatty acid metabolism in thyroid carcinoma. Front Oncol. 2021;11:737127. doi: 10.3389/fonc.2021.737127
   PubMedGoogle Scholar
• Renaud E, Riegel K, Romero R, et al. Multiomic analysis of papillary thyroid cancers identifies BAIAP2L1-BRAF fusion and requirement of TRIM25, PDE5A and PKCδ for tumorigenesis. Mol Cancer. 2022;21(1):195. doi: 10.1186/s12943-022-01665-y
   PubMed Web of Science ®Google Scholar
• Sun Y, Li L, Zhou Y, et al. Stratification of follicular thyroid tumours using data-independent acquisition proteomics and a comprehensive thyroid tissue spectral library. Mol Oncol. 2022;16(8):1611–1624. doi: 10.1002/1878-0261.13198
   PubMed Web of Science ®Google Scholar
• Huang D, Zhang H, Li L, et al. Proteotypic Differences of Follicular-Patterned Thyroid Neoplasms. Front Endocrinol. 2022;13:854611. doi: 10.3389/fendo.2022.854611
   PubMed Web of Science ®Google Scholar
• Ucal Y, Tokat F, Duren M, et al. Peptide Profile Differences of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features, Encapsulated Follicular Variant, and Classical Papillary Thyroid Carcinoma: An Application of Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging. Thyroid. 2019;29(8):1125–1137. doi: 10.1089/thy.2018.0392
   PubMed Web of Science ®Google Scholar
• García-Vence M, Chantada-Vázquez MDP, Cameselle-Teijeiro JM, et al. A novel nanoproteomic approach for the identification of molecular Targets associated with thyroid tumors. Nanomaterials (Basel). 2020;10(12):2370. doi: http://dx.doi.org/10.3390/nano10122370
   PubMedGoogle Scholar
• Piga I, L’Imperio V, Principi L, et al. Spatially resolved molecular approaches for the characterisation of non-invasive follicular tumours with papillary-like features (NIFTPs). IJMS. 2023;24(3):2567. doi: 10.3390/ijms24032567
   Google Scholar
• Gawin M, Wojakowska A, Pietrowska M, et al. Proteome profiles of different types of thyroid cancers. Mol Cell Endocrinol. 2018;472:68–79. doi: 10.1016/j.mce.2017.11.020
   PubMed Web of Science ®Google Scholar
• Kurczyk A, Gawin M, Chekan M, et al. Classification of thyroid tumors based on mass spectrometry imaging of tissue Microarrays; a single-pixel approach. IJMS. 2020;21(17):6289. doi: 10.3390/ijms21176289
   Google Scholar
• Smith A, Galli M, Piga I, et al. Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging. J Proteomics. 2019;191:114–123. doi: 10.1016/j.jprot.2018.03.021
   PubMed Web of Science ®Google Scholar
• Shi X, Sun Y, Shen C, et al. Integrated proteogenomic characterization of medullary thyroid carcinoma. Cell Discov. 2022;8(1):120. doi: 10.1038/s41421-022-00479-y
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou S, Wang D, et al. Complement C4-A and plasminogen as potential biomarkers for prediction of papillary thyroid carcinoma. Front Endocrinol. 2021;12:737638. doi: 10.3389/fendo.2021.737638
   PubMed Web of Science ®Google Scholar
• Lu H, Pan Y, Ruan Y, et al. Biomarker discovery for early diagnosis of papillary thyroid carcinoma using high-throughput enhanced quantitative plasma proteomics. J Proteome Res. 2023;22(10):3200–3212. doi: http://dx.doi.org/10.1021/acs.jproteome.3c00187
   PubMed Web of Science ®Google Scholar
• Lauc G, Trbojević-Akmačić I. The role of glycosylation in health and disease. Springer Nature Switzerland AG; 2021 doi:10.1007/978-3-030-70115-4
   Google Scholar
• Zhang Y, Zhao W, Zhao Y, et al. Comparative glycoproteomic profiling of human body fluid between healthy controls and patients with papillary thyroid carcinoma. J Proteome Res. 2020;19(7):2539–2552. doi: 10.1021/acs.jproteome.9b00672
   PubMed Web of Science ®Google Scholar
• Zhang Z, Reiding KR, Wu J, et al. Distinguishing benign and malignant thyroid nodules and identifying lymph node metastasis in papillary thyroid cancer by plasma -glycomics. Front Endocrinol. 2021;12:692910. doi: 10.3389/fendo.2021.692910
   PubMed Web of Science ®Google Scholar
• Sun Z, Feng D, Jiang L, et al. Integrated proteomic and metabolomic analysis of plasma reveals regulatory pathways and key elements in thyroid cancer. Mol Omics. 2023. doi: 10.1039/d3mo00142c
   Web of Science ®Google Scholar
• Denti V, Piga I, Guarnerio S, et al. Antigen Retrieval and its effect on the MALDI-MSI of lipids in formalin-fixed paraffin-embedded tissue. J Am Soc Mass Spectrom. 2020;31(8):1619–1624. doi: 10.1021/jasms.0c00208
   PubMed Web of Science ®Google Scholar
• Ly A, Buck A, Balluff B, et al. High-mass-resolution MALDI mass spectrometry imaging of metabolites from formalin-fixed paraffin-embedded tissue. Nat Protoc. 2016;11(8):1428–1443. doi: 10.1038/nprot.2016.081
   PubMed Web of Science ®Google Scholar
• Lee GB, Lee JC, Moon MH. Plasma lipid profile comparison of five different cancers by nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry. Anal Chim Acta. 2019;1063:117–126. doi: 10.1016/j.aca.2019.02.021
   PubMed Web of Science ®Google Scholar
• Huang L, Mao X, Sun C, et al. Molecular pathological diagnosis of thyroid tumors using Spatially resolved metabolomics. Molecules. 2022;27(4):1390. doi: 10.3390/molecules27041390
   PubMed Web of Science ®Google Scholar
• DeHoog RJ, Zhang J, Alore E, et al. Preoperative metabolic classification of thyroid nodules using mass spectrometry imaging of fine-needle aspiration biopsies. Proc Natl Acad Sci U S A. 2019;116(43):21401–21408. doi: 10.1073/pnas.1911333116
   PubMed Web of Science ®Google Scholar
• Rezig L, Servadio A, Torregrossa L, et al. Diagnosis of post-surgical fine-needle aspiration biopsies of thyroid lesions with indeterminate cytology using HRMAS NMR-based metabolomics. Metabolomics. 2018;14(10):141. doi: 10.1007/s11306-018-1437-6
   PubMed Web of Science ®Google Scholar
• Skorupa A, Ciszek M, Chmielik E, et al. Shared and unique metabolic features of the malignant and benign thyroid lesions determined with use of H HR MAS NMR spectroscopy. Sci Rep. 2021;11:1344. doi: 10.1038/s41598-020-79565-8
   PubMed Web of Science ®Google Scholar
• Seo JW, Han K, Lee J, et al. Application of metabolomics in prediction of lymph node metastasis in papillary thyroid carcinoma. PLoS One. 2018;13(3):e0193883. doi: 10.1371/journal.pone.0193883
   PubMed Web of Science ®Google Scholar
• Wang T, Sun Z, Wang Y, et al. Diagnosis of papillary thyroid carcinoma by H NMR spectroscopy-based metabolomic analysis of whole blood. Drug Discov Ther. 2020;14:187–196. doi: 10.5582/ddt.2020.03062
   PubMed Web of Science ®Google Scholar
• DeHoog RJ, King ME, Keating MF, et al. Intraoperative identification of thyroid and parathyroid tissues during human endocrine surgery using the MasSpec pen. JAMA Surg. 2023;158(10):1050. doi: 10.1001/jamasurg.2023.3229
   PubMed Web of Science ®Google Scholar
• Szulc DA. Manganese-based positive-contrast MRI for non-invasive monitoring of biomaterials and cells in tissue engineering. 2020.
   Google Scholar
• Zhang J, Rector J, Lin JQ, et al. Nondestructive tissue analysis for ex vivo and in vivo cancer diagnosis using a handheld mass spectrometry system. Sci Transl Med. 2017;9. doi: 10.1126/scitranslmed.aan3968
   Web of Science ®Google Scholar
• Sutton RT, Pincock D, Baumgart DC, et al. An overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ Digit Med. 2020;3:17. doi: 10.1038/s41746-020-0221-y
   PubMed Web of Science ®Google Scholar
• Aversano L, Bernardi ML, Cimitile M, et al. A systematic review on artificial intelligence techniques for detecting thyroid diseases. PeerJ Comput Sci. 2023;9:e1394. doi: 10.7717/peerj-cs.1394
   PubMed Web of Science ®Google Scholar
• Girolami I, Marletta S, Pantanowitz L, et al. Impact of image analysis and artificial intelligence in thyroid pathology, with particular reference to cytological aspects. Cytopathology. 2020;31(5):432–444. doi: 10.1111/cyt.12828
   PubMed Web of Science ®Google Scholar
• Kumar Y, Gupta S, Singla R, et al. A systematic review of artificial intelligence techniques in cancer prediction and diagnosis. Arch Comput Methods Eng. 2022;29(4):2043–2070. doi: 10.1007/s11831-021-09648-w
   PubMed Web of Science ®Google Scholar
• Rajkomar A, Dean J, Kohane I. Machine learning in Medicine. N Engl J Med. 2019;380(14):1347–1358. doi: 10.1056/NEJMra1814259
   PubMed Web of Science ®Google Scholar
• Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24–29. doi: 10.1038/s41591-018-0316-z
   PubMed Web of Science ®Google Scholar
• Bera K, Schalper KA, Rimm DL, et al. Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 2019;16:703–715. doi: 10.1038/s41571-019-0252-y
   PubMed Web of Science ®Google Scholar
• Asan U, Ercan S. An Introduction to Self-Organizing Maps. In Kahraman C, editor. Computational Intelligence Systems in Industrial Engineering. Atlantis Computational Intelligence Systems. Vol. 6, Paris: Atlantis Press; 2012. doi:10.2991/978-94-91216-77-0_14
   Google Scholar
• Hautaniemi S, Yli-Harja O, Astola J, et al. Analysis and visualization of gene expression microarray data in human cancer using self-organizing maps. MACH LEARN. 2003;52:45–66. doi: 10.1023/A:1023941307670
   Web of Science ®Google Scholar
• Lee B, Yamanakkanavar N, Choi JY, et al. Automatic segmentation of brain MRI using a novel patch-wise U-net deep architecture. PLoS One. 2020;15(8):e0236493. doi: 10.1371/journal.pone.0236493
   PubMed Web of Science ®Google Scholar
• Solorio-Fernández S, Carrasco-Ochoa JA, Martínez-Trinidad JF. A review of unsupervised feature selection methods. Artif Intell Rev. 2019;53:907–948. doi: 10.1007/s10462-019-09682-y
   Web of Science ®Google Scholar
• Nobile MS, Capitoli G, Sowirono V, et al. Unsupervised neural networks as a support tool for pathology diagnosis in MALDI-MSI experiments: a case study on thyroid biopsies. Expert Syst Appl. 2023;215:119296.
   Web of Science ®Google Scholar
• Cao C-L, Li Q-L, Tong J, et al. Artificial intelligence in thyroid ultrasound. Front Oncol. 2023;13:1060702. doi: 10.3389/fonc.2023.1060702
   PubMedGoogle Scholar
• Zhang X, Lee VC, Rong J, et al. Deep convolutional neural networks in thyroid disease detection: a multi-classification comparison by ultrasonography and computed tomography. Comput Methods Programs Biomed. 2022;220:106823. doi: 10.1016/j.cmpb.2022.106823
   PubMed Web of Science ®Google Scholar
• Wang Y, Guan Q, Lao I, et al. Using deep convolutional neural networks for multi-classification of thyroid tumor by histopathology: a large-scale pilot study. Ann Transl Med. 2019;7:468. doi: 10.21037/atm.2019.08.54
   PubMed Web of Science ®Google Scholar
• Duan W, Gao L, Liu J, et al. Computer-assisted fine-needle aspiration cytology of thyroid using two-stage refined convolutional neural network. Electronics. 2022;11(24):4089. doi: 10.3390/electronics11244089
   Web of Science ®Google Scholar
• Zhu X, Chen C, Guo Q, et al. Deep learning-based Recognition of different thyroid cancer categories using whole frozen-slide images. Front Bioeng Biotechnol. 2022;10:857377. doi: 10.3389/fbioe.2022.857377
   PubMed Web of Science ®Google Scholar
• Sanyal P, Mukherjee T, Barui S, et al. Artificial intelligence in Cytopathology: a neural network to identify papillary carcinoma on thyroid fine-needle aspiration cytology smears. J Pathol Inform. 2018;9:43. doi: 10.4103/jpi.jpi_43_18
   PubMedGoogle Scholar
• Ambags EL, Capitoli G, Imperio VL, et al. Assisting clinical practice with fuzzy probabilistic decision trees [internet]. 2023 [cited 2023 Jul 27]. Available from: http://arxiv.org/abs/2304.07788.
   Google Scholar
• Thomasian NM, Kamel IR, Bai HX. Machine intelligence in non-invasive endocrine cancer diagnostics. Nat Rev Endocrinol. 2022;18(2):81–95. doi: 10.1038/s41574-021-00543-9
   PubMed Web of Science ®Google Scholar
• No title. [Internet]. [cited 2023 Jul 27]. Available from: https://www.ams-inc.on.ca/wp-content/uploads/2020/02/The-Impact-of-AI-on-clinical-judgement.pdf.
   Google Scholar
• Obermeyer Z, Topol EJ. Artificial intelligence, bias, and patients’ perspectives. Lancet. 2021;397(10289):2038. doi: 10.1016/S0140-6736(21)01152-1
   PubMed Web of Science ®Google Scholar
• Pagni F, L’Imperio V, Bono F, et al. Proteome analysis in thyroid pathology. Expert Rev Proteomics. 2015;12(4):375–390. doi: 10.1586/14789450.2015.1062369
   PubMed Web of Science ®Google Scholar
• Pagni F, Mainini V, Garancini M, et al. Proteomics for the diagnosis of thyroid lesions: preliminary report. Cytopathology. 2015;26(5):318–324. doi: 10.1111/cyt.12166
   PubMed Web of Science ®Google Scholar
• Mainini V, Pagni F, Garancini M, et al. An alternative approach in endocrine pathology research: MALDI-IMS in papillary thyroid carcinoma. Endocr Pathol. 2013;24(4):250–253. doi: 10.1007/s12022-013-9273-8
   PubMed Web of Science ®Google Scholar
• Galli M, Pagni F, De Sio G, et al. Proteomic profiles of thyroid tumors by mass spectrometry-imaging on tissue microarrays. Biochim Biophys Acta Proteins Proteomics. 2017;1865(7):817–827. doi: 10.1016/j.bbapap.2016.11.020
   PubMed Web of Science ®Google Scholar